Bionano Genomics, Inc.
No enriched coverage for $BNGO in the last 7 days.
Bionano Genomics (BNGO) reported Q2 2026 revenue of $8.2 million, up 21% year over year, driven by higher OGM consumables sales. Flow cell sales rose 27% to 9,219 units, though the company said it is backordered due to manufacturing constraints. Installed base was 397 systems. Adjusted gross margin was 53%. Full-year 2026 revenue guidance is $31 million to $33 million.
Bionano Genomics reported Q2 2026 results on an earnings call, citing 30% YoY consumables growth and record 53% adjusted gross margin from higher adoption and efficiency. Full-year 2026 revenue guidance was raised to $31M-$33M. Flow-cell backorders and manufacturing constraints are expected to ease by Q4 2026. Software revenue fell 16% YoY.
Bionano Genomics, Inc. (BNGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bionano Reports Second Quarter 2026 Results and Provides a Business Update Conference call today, August 10, 2026, at 4:30 PM ET SAN DIEGO, August 10, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarte
Recent BNGO coverage spans financial news, earnings and technology.
In the last 30 days, BNGO insiders filed 1 SEC Form 4 transaction — 1 purchase ($5K) and no sales. The most active reporter was Luderer Albert, Interim Chief Executive, with 1 filing.
The call provides fresh guidance and operational constraints that directly affect near-term revenue timing and longer-term consumables growth.
Guidance raise plus a stated path to clear flow-cell constraints should improve near-term revenue visibility, but backlog and supply timing remain key risks.
The 8-K provides fresh quarterly datapoints plus explicit Q3 and full-year 2026 revenue guidance, which can reset near-term expectations.
The article is a validation/clinical-evidence update for Bionano’s OGM platform, potentially supporting adoption narratives with researchers/clinicians.
The director's stock option grant is a standard form of equity compensation, indicating confidence in the company's future. Since the event is neutral in sentiment and impact, it is unlikely to cause significant short-term price movements.
alphai scores every news story that mentions BNGO with an AI model for sentiment and relevance, and aggregates insider trades from Bionano Genomics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bionano Genomics (BNGO) reported Q2 2026 revenue of $8.2 million, up 21% year over year, driven by higher OGM consumables sales. Flow cell sales rose 27% to 9,219 units, though the company said it is backordered due to manufacturing constraints. Installed base was 397 systems. Adjusted gross margin was 53%. Full-year 2026 revenue guidance is $31 million to $33 million.
6 min readBionano Genomics reported Q2 2026 results on an earnings call, citing 30% YoY consumables growth and record 53% adjusted gross margin from higher adoption and efficiency. Full-year 2026 revenue guidance was raised to $31M-$33M. Flow-cell backorders and manufacturing constraints are expected to ease by Q4 2026. Software revenue fell 16% YoY.
7 min readBionano Genomics, Inc. (BNGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bionano Reports Second Quarter 2026 Results and Provides a Business Update Conference call today, August 10, 2026, at 4:30 PM ET SAN DIEGO, August 10, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarte
6 min readBionano Genomics (Nasdaq: BNGO) said 13 studies published in 2026 covering 730 samples across multiple countries evaluated optical genome mapping (OGM) for structural-variant detection in reproductive health and prenatal genetic disorders. The company cited results including 1-in-4 diagnoses in unexplained infertility (220 subjects) and up to 99.03% prenatal concordance (217 samples).
4 min readBionano Genomics director Kristiina Vuori, MD, was granted 9,149 stock options at an exercise price of $1.19 per share. These options, part of her compensation, will vest in equal monthly installments over 12 months or fully upon a Change of Control, and expire on May 13, 2036. This transaction is considered a neutral event in terms of filing impact and sentiment, as it represents equity compensation rather than an open-market purchase.
2 min readBionano Genomics, Inc. (BNGO) reported a Q1 loss of $0.76 per share, outperforming the Zacks Consensus Estimate of a $0.81 loss and surpassing year-ago revenues. The company posted revenues of $6.69 million for the quarter ended March 2026, beating estimates by 2.88%. Despite an underperforming stock year-to-date, its earnings outlook is favorable, earning it a Zacks Rank #2 (Buy).
3 min readBionano Genomics, Inc. (Nasdaq: BNGO) announced it will report its first quarter 2026 financial results and discuss recent corporate progress during a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time. Interested parties can register for the event and a replay will be available on the company's investor relations website for at least 30 days.
2 min readH.C. Wainwright has lowered its price target for Bionano Genomics (NASDAQ:BNGO) to $6 from $7, while maintaining a Buy rating. This adjustment is primarily due to an increased share count, despite the stock trading near its 52-week low and an InvestingPro analysis suggesting it may be undervalued. Bionano Genomics reported a revenue decline for Q4 2025 and the full year 2025, but management provided 2026 revenue guidance indicating potential topline growth of up to 16%.
3 min readBionano Genomics reported preliminary unaudited financial results for Q4 and full-year 2025, highlighting a pivotal year of business model transformation, improved financial profile, and expanded adoption of optical genome mapping (OGM) solutions. The company anticipates full-year 2025 revenue between $28.4 million and $28.6 million, with 32 new OGM systems installed, bringing the total installed base to 387. Bionano also noted significant reimbursement progress and growth in published clinical research supporting OGM.
3 min readImage source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
5 min read
